Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined analysis of the trials used for registration and postmarketing data.

Witjes JA, Gomella LG, Stenzl A, Chang SS, Zaak D, Grossman HB.

Urology. 2014 Jul;84(1):122-6. doi: 10.1016/j.urology.2014.03.006. Epub 2014 Apr 24.

PMID:
24768013
2.

Hexaminolevulinate blue light cystoscopy: a review of its use in the diagnosis of bladder cancer.

Yang LP.

Mol Diagn Ther. 2014 Feb;18(1):105-16. doi: 10.1007/s40291-013-0068-x. Review.

PMID:
24248555
3.

Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?

Geavlete B, Multescu R, Georgescu D, Jecu M, Stanescu F, Geavlete P.

BJU Int. 2012 Feb;109(4):549-56. doi: 10.1111/j.1464-410X.2011.10374.x. Epub 2011 Jun 28.

4.

Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA.

Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD.

Nat Rev Urol. 2014 Oct;11(10):589-96. doi: 10.1038/nrurol.2014.245. Epub 2014 Sep 23. Review.

PMID:
25245244
5.

Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.

Witjes JA, Babjuk M, Gontero P, Jacqmin D, Karl A, Kruck S, Mariappan P, Palou Redorta J, Stenzl A, van Velthoven R, Zaak D.

Eur Urol. 2014 Nov;66(5):863-71. doi: 10.1016/j.eururo.2014.06.037. Epub 2014 Jul 4. Review.

PMID:
25001887
6.

[Initial experience in the diagnosis and treatment of superficial bladder tumors with Hexvix].

Abascal Junquera JM, Hevia Suárez M, Abascal García JM, Estébanez C, Astudillo A, Abascal R.

Arch Esp Urol. 2008 May;61(4):475-82; discussion 482-3. Spanish.

PMID:
18592765
7.

A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer.

Grossman HB, Gomella L, Fradet Y, Morales A, Presti J, Ritenour C, Nseyo U, Droller MJ; PC B302/01 Study Group.

J Urol. 2007 Jul;178(1):62-7. Epub 2007 May 11.

PMID:
17499283
8.

Hexaminolevulinate fluorescence cystoscopy and transurethral resection of the bladder in noninvasive bladder tumors.

Geavlete B, Multescu R, Georgescu D, Geavlete P.

J Endourol. 2009 Jun;23(6):977-81. doi: 10.1089/end.2008.0574.

PMID:
19473068
9.
10.

HAL fluorescence cystoscopy and TURB one year of Romanian experience.

Geavlete B, Mulţescu R, Georgescu D, Jecu M, Geavlete P.

J Med Life. 2009 Apr-Jun;2(2):185-90.

11.

Effectiveness of hexaminolevulinate fluorescence cystoscopy for the diagnosis of non-muscle-invasive bladder cancer in daily clinical practice: a Spanish multicentre observational study.

Palou J, Hernández C, Solsona E, Abascal R, Burgués JP, Rioja C, Cabrera JA, Gutiérrez C, Rodríguez O, Iborra I, Herranz F, Abascal JM, Conde G, Oliva J.

BJU Int. 2015 Jul;116(1):37-43. doi: 10.1111/bju.13020. Epub 2015 Mar 25.

12.

Hexaminolevulinate-guided transurethral resection of non-muscle-invasive bladder cancer does not reduce the recurrence rates after a 2-year follow-up: a prospective randomized trial.

Gkritsios P, Hatzimouratidis K, Kazantzidis S, Dimitriadis G, Ioannidis E, Katsikas V.

Int Urol Nephrol. 2014 May;46(5):927-33. doi: 10.1007/s11255-013-0603-z. Epub 2013 Nov 19.

PMID:
24249423
13.

Flexible cystoscopy assisted by hexaminolevulinate induced fluorescence: a new approach for bladder cancer detection and surveillance?

Loidl W, Schmidbauer J, Susani M, Marberger M.

Eur Urol. 2005 Mar;47(3):323-6. Epub 2004 Dec 30.

PMID:
15716195
14.

Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.

Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, Witjes JA, Stenzl A, Jichlinski P, Jocham D.

Eur Urol. 2013 Nov;64(5):846-54. doi: 10.1016/j.eururo.2013.03.059. Epub 2013 Apr 8. Review.

PMID:
23602406
15.

A comparison of hexaminolevulinate (Hexvix(®)) fluorescence cystoscopy and white-light cystoscopy for detection of bladder cancer: results of the HeRo observational study.

Lapini A, Minervini A, Masala A, Schips L, Pycha A, Cindolo L, Giannella R, Martini T, Vittori G, Zani D, Bellomo F, Cosciani Cunico S.

Surg Endosc. 2012 Dec;26(12):3634-41. doi: 10.1007/s00464-012-2387-0. Epub 2012 Jun 23.

PMID:
22729704
16.
17.

Role of hexaminolevulinate-guided fluorescence cystoscopy in bladder cancer: critical analysis of the latest data and European guidance.

Malmström PU, Grabe M, Haug ES, Hellström P, Hermann GG, Mogensen K, Raitanen M, Wahlqvist R.

Scand J Urol Nephrol. 2012 Apr;46(2):108-16. doi: 10.3109/00365599.2011.633279. Epub 2011 Nov 16.

PMID:
22087730
18.

Photodynamic therapy of bladder cancer - a phase I study using hexaminolevulinate (HAL).

Bader MJ, Stepp H, Beyer W, Pongratz T, Sroka R, Kriegmair M, Zaak D, Welschof M, Tilki D, Stief CG, Waidelich R.

Urol Oncol. 2013 Oct;31(7):1178-83. doi: 10.1016/j.urolonc.2012.02.007. Epub 2012 Mar 21.

PMID:
22440147
19.

Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy.

Schmidbauer J, Witjes F, Schmeller N, Donat R, Susani M, Marberger M; Hexvix PCB301/01 Study Group.

J Urol. 2004 Jan;171(1):135-8.

PMID:
14665861
20.

Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study.

Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, Muschter R, Popken G, König F, Knüchel R, Kurth KH.

J Urol. 2005 Sep;174(3):862-6; discussion 866.

PMID:
16093971

Supplemental Content

Support Center